BevilacquaL, et al. (2021) Role of nitric oxide signaling in the antidepressant mechanism of action of ketamine: a randomized controlled trial. J Psychopharmacol35.
2.
FalhammarHSkovJCalissendorffJ, et al. (2021) Reduced risk for hospitalization due to hyponatremia in lithium treated patients: a Swedish population-based case-control study. J Psychopharmacol35.
3.
GolicMAiffHAttmanP, et al. (2021) Starting lithium in patients with compromised renal function – is it wise?J Psychopharmacol35.
4.
JelenLAYoungAHStoneJM (2021) Ketamine: a tale of two enantiomers. J Psychopharmacol35.
5.
LattieDTNehoffHNeehoffS, et al. (2021) Anxiolytic effects of acute and maintenance ketamine, as assessed by the Fear Questionnaire subscales and the Spielberger State Anxiety Rating Scale. J Psychopharmacol35.
6.
LuccheseACMagalhaesEDel SantL, et al. (2021) Repeated subcutaneous esketamine for treatment-resistant depression: impact of the degree of treatment resistance and anxiety comorbidity. J Psychopharmacol35.
7.
McIntyreRSRodriguesNBLipsitzO, et al. (2021) The effectiveness of intravenous ketamine in adults with treatment-resistant major depressive disorder and bipolar disorder presenting with prominent anxiety: results from the Canadian Rapid Treatment Center of Excellence. J Psychopharmacol35.
8.
MahaseE (2019) Esketamine is approved in Europe for treating resistant major depressive disorder. BMJ367: l7069.
9.
MemonARogersIFitzsimmonsSMDD, et al. (2020) Association between naturally occurring lithium in drinking water and suicide rates: Systematic review and meta-analysis of ecological studies. Br J Psychiatry27: 1–12.
10.
PoelsESterrenburgKWierdsmaA, et al. (2021) Lithium exposure during pregnancy increases foetal growth. J Psychopharmacol35.
11.
RothbergRLAzhariNHaugNA, et al. (2021) Mystical-type experiences occasioned by ketamine mediate its impact on at-risk drinking: results from a randomized, controlled trial. J Psychopharmacol35.
12.
RoyAThaiMKlimes-DougahB, et al. (2021) Brain entropy and neurotrophic molecular markers accompanying clinical improvement after ketamine: preliminary evidence in adolescents with treatment-resistant depression. J Psychopharmacol35.
13.
SwainsonJMcGirrABlierP, et al. (2020) The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the use of racemic ketamine in adults with major depressive disorder. Can J Psychiatry. Epub ahead of print 11November2020. DOI: 10.1177/0706743720970860.
14.
ZhouYLiuWWangC, et al. (2021) Cardiovascular effects of repeated subanaesthetic ketamine infusion in depression. J Psychopharmacol35.
